Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G.

EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14.

2.

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.

Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

EBioMedicine. 2018 Dec;38:100-112. doi: 10.1016/j.ebiom.2018.11.004. Epub 2018 Nov 25.

3.

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.

Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G.

Mol Ther Nucleic Acids. 2017 Dec 15;9:251-262. doi: 10.1016/j.omtn.2017.06.023. Epub 2017 Jul 5.

4.

Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.

Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G.

Cell Discov. 2017 Sep 12;3:17029. doi: 10.1038/celldisc.2017.29. eCollection 2017.

5.

Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.

Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL.

Oncotarget. 2017 Mar 21;8(12):20145-20164. doi: 10.18632/oncotarget.15525.

6.

Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).

Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2017 Jun;16(6):1114-1123. doi: 10.1158/1535-7163.MCT-16-0541. Epub 2017 Mar 6.

7.

Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.

Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

Cancer Res. 2016 Dec 15;76(24):7194-7207. Epub 2016 Oct 14. Erratum in: Cancer Res. 2018 Jun 15;78(12):3402.

8.

A study on evaluation of apoptosis and expression of bcl-2-related marker in wound healing of streptozotocin-induced diabetic rats.

Bhan S, Mitra R, Arya AK, Pandey HP, Tripathi K.

ISRN Dermatol. 2013 Oct 7;2013:739054. doi: 10.1155/2013/739054. eCollection 2013.

9.

Development of a novel rapid immunodiagnostic kit based on flagellar 40 kDa antigen epitope for the detection of typhoid fever in Indian patients.

Mitra R, Bhan S, Nath G, Kumar N, Ali Z.

ScientificWorldJournal. 2013;2013:363652. doi: 10.1155/2013/363652. Epub 2013 Feb 5.

10.

Serum prolidase activity, oxidant and antioxidant status in nonulcer dyspepsia and healthy volunteers.

Kumari S, Verma AK, Rungta S, Mitra R, Srivastava R, Kumar N.

ISRN Biochem. 2013 Oct 29;2013:182601. doi: 10.1155/2013/182601. eCollection 2013.

11.

Dual targeting of EphA2 and FAK in ovarian carcinoma.

Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK.

Cancer Biol Ther. 2009 Jun;8(11):1027-34. Epub 2009 Jun 24.

12.

Ultraspecific probes for high throughput HLA typing.

Feng C, Putonti C, Zhang M, Eggers R, Mitra R, Hogan M, Jayaraman K, Fofanov Y.

BMC Genomics. 2009 Feb 20;10:85. doi: 10.1186/1471-2164-10-85.

13.

Effect of sirolimus treatment on gene expression in renal transplant patients.

Vickers K, Mitra R, Kapoor M, Kahan B, Morrisett JD.

World J Surg. 2007 Apr;31(4):644-53.

PMID:
17334862
14.

Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein.

Stemke-Hale K, Hennessy B, Mills GB, Mitra R.

Curr Oncol Rep. 2006 Nov;8(6):484-91. Review.

PMID:
17040626
15.

Data integration gets 'Sloppy'.

Almeida JS, Chen C, Gorlitsky R, Stanislaus R, Aires-de-Sousa M, Eleutério P, Carriço J, Maretzek A, Bohn A, Chang A, Zhang F, Mitra R, Mills GB, Wang X, Deus HF.

Nat Biotechnol. 2006 Sep;24(9):1070-1. No abstract available.

PMID:
16964209
16.

Human-blind probes and primers for dengue virus identification.

Putonti C, Chumakov S, Mitra R, Fox GE, Willson RC, Fofanov Y.

FEBS J. 2006 Jan;273(2):398-408.

17.

Application of protein lysate microarrays to molecular marker verification and quantification.

Ramaswamy A, Lin E, Chen I, Mitra R, Morrisett J, Coombes K, Ju Z, Kapoor M.

Proteome Sci. 2005 Nov 10;3:9.

Supplemental Content

Loading ...
Support Center